Purple Biotech Ltd.
Purple Biotech Ltd.
03/25/2026 | Press release | Distributed by Public on 03/25/2026 06:13
AI Collaboration with Converge Bio to Accelerate Development of its Next-Generation Tri-Specific Antibody Platform
|
||||||||||||||||||||||||||||||
| Other Report or Announcement | ||||||||||||||||||||||||||||||
| Regulation 5 of the Securities Regulations, (Periodic and Immediate Reports of Foreign Corporation) 5761-2000 | ||||||||||||||||||||||||||||||
| References of previous documents relating to this matter(the reference does not constitute incorporation by reference): | ||||||||||||||||||||||||||||||
| Stock Exchange/Market: NASDAQ CM | Date of revision of form structure: 06/08/2024 | |||||||||||||||||||||||||||||
| Address: Oppenheimer, Science Park 4, Rehovot7670104 , IsraelTel: 03-9333121, 03-9311321Fax: 03-5097196 | ||||||||||||||||||||||||||||||
| E-mail address: [email protected] Company site: www.kitovpharma.com | ||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||
| Previous names of reporting entity: KITOV PHARMA LTD, KITOV PHARMACEUTICALS HOLDINGS LTD, MAINROM LINE LOGISTICS LTD, ORLINE DEVELOPMENT AND INVESTMENT LTD, KADURY & HAI (MOLET) ASSETS & INVESTMENTS LTD, | ||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||
| Name of the Signatory: Zadik Avital Position of Signatory in the reporting corporation: Director of Finance Name of Employer Company: | ||||||||||||||||||||||||||||||
| Address: Oppenheimer, Science Park 4, Rehovot7670104Telephone: 052-8882715Facsimile: 03-5097196E-mail: [email protected] | ||||||||||||||||||||||||||||||
Purple Biotech Ltd. published this content on March 25, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on March 25, 2026 at 12:13 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]